Apremilast

Generic Name
Apremilast
Brand Names
Otezla, Apremilast Accord
Drug Type
Small Molecule
Chemical Formula
C22H24N2O7S
CAS Number
608141-41-9
Unique Ingredient Identifier
UP7QBP99PN
Background

Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the tr...

Indication

Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.

Associated Conditions
Psoriasis Vulgaris (Plaque Psoriasis), Active Psoriatic arthritis, Ulceration of the mouth
Associated Therapies
-
Clinical Trials
Related News

Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)

Completed
Conditions
Nail Psoriasis
Interventions
Drug: Apremilast
First Posted Date
2018-08-06
Last Posted Date
2020-07-29
Lead Sponsor
Hospital de Granollers
Target Recruit Count
45
Registration Number
NCT03616561
Locations
🇪🇸

Hospital General de Granollers, Granollers, Barcelona, Spain

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: BMS-986165
Other: Placebo
Drug: Apremilast
First Posted Date
2018-08-02
Last Posted Date
2022-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1020
Registration Number
NCT03611751
Locations
🇺🇸

Interspond - Savin Medical Group, Miami Lakes, Florida, United States

🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 195 locations

Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)

Completed
Conditions
Arthritis, Psoriatic
Interventions
Drug: Apremilast
First Posted Date
2018-08-01
Last Posted Date
2024-06-05
Lead Sponsor
Amgen
Target Recruit Count
102
Registration Number
NCT03608657
Locations
🇨🇦

Toronto Western Hospital, University Health Network, Toronto, Canada

🇨🇦

The Waterside Clinic, Barrie, Canada

🇨🇦

Adachi Medicine Professional Corporation, Hamilton, Canada

and more 16 locations

Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)

Phase 4
Completed
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Drug: Apremilast
First Posted Date
2018-05-11
Last Posted Date
2022-05-09
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
20
Registration Number
NCT03521687
Locations
🇺🇸

Mount Sinai West Dermatology, New York, New York, United States

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

Phase 2
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Apremilast
First Posted Date
2018-02-22
Last Posted Date
2023-01-20
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
28
Registration Number
NCT03442088
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia

Phase 4
Conditions
Frontal Fibrosing Alopecia
Interventions
Drug: Apremilast
First Posted Date
2018-02-06
Last Posted Date
2018-07-16
Lead Sponsor
Bellevue Dermatology
Target Recruit Count
20
Registration Number
NCT03422640
Locations
🇺🇸

Bellevue Dermatology, Bellevue, Washington, United States

A Study Examining the Medication Apremilast as Treatment for Chronic Itch

Phase 2
Completed
Conditions
Itch
Interventions
Drug: Apremilast
First Posted Date
2017-08-03
Last Posted Date
2021-07-13
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
10
Registration Number
NCT03239106
Locations
🇺🇸

Washington University Division of Dermatology, Saint Louis, Missouri, United States

Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis

First Posted Date
2017-06-19
Last Posted Date
2017-10-17
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
56
Registration Number
NCT03191539

Medication Development in Alcoholism: Apremilast Versus Placebo

Phase 2
Completed
Conditions
Alcohol Use Disorder
Interventions
Drug: Apremilast
Drug: Placebo
First Posted Date
2017-06-05
Last Posted Date
2022-09-16
Lead Sponsor
The Scripps Research Institute
Target Recruit Count
51
Registration Number
NCT03175549
Locations
🇺🇸

The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States

An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema

First Posted Date
2017-05-19
Last Posted Date
2021-10-08
Lead Sponsor
Technical University of Munich
Target Recruit Count
31
Registration Number
NCT03160248
Locations
🇩🇪

Technical University Munich - Department of Dermatology, Munich, Bavaria, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy